Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT)

BACKGROUND: Uveal melanoma is characterised by mutations in GNAQ and GNA11, resulting in Ras/Raf/MEK/ERK pathway activation. Treatment with selumetinib (AZD6244, ARRY-142886), a MEK1/2 inhibitor, results in antitumour effects in uveal melanoma pre-clinical models. A randomised phase II trial demonst...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:BMC Cancer
Glavni autori: Carvajal, Richard D., Schwartz, Gary K., Mann, Helen, Smith, Ian, Nathan, Paul D.
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2015
Teme:
Study Protocol
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4460965/
https://ncbi.nlm.nih.gov/pubmed/26059332
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-015-1470-z
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items